Navigation Links
Fairview Specialty Pharmacy Signs Contract With BioMarin for Distribution of Kuvan(TM)
Date:1/8/2008

MINNEAPOLIS, Jan. 8 /PRNewswire/ -- Fairview Specialty Pharmacy today announced that it has been selected by BioMarin Pharmaceutical, Inc. to be a participating pharmacy in the specialty pharmacy limited distribution network for Kuvan(TM) (sapropterin dihydrochloride) Tablets, the first specific drug therapy approved for the treatment of phenylketonuria (PKU).

Kuvan was approved by the U.S. Food and Drug Administration (FDA) on December 13 and is now available through Fairview Specialty Pharmacy for patients who are prescribed this treatment by their physicians.

Kari Amundson, Fairview Specialty Pharmacy Director, commented, "We are pleased to be selected by BioMarin to launch this new drug therapy. This distributor agreement is critical to our growth strategy and our ability to provide comprehensive care to patients across the Midwest and at the University of Minnesota Medical Center, Fairview."

"Kuvan is an important breakthrough in the treatment of PKU," said Chester Whitley, Ph.D, M.D., Director of Advanced Therapy Services at the University of Minnesota Medical Center, Fairview. "We are fortunate to have Fairview Specialty Pharmacy as one of the limited specialty distribution providers for this drug."

"We are extremely pleased to be working with specialty pharmacies like Fairview to make this promising new treatment option available to PKU patients and their families," said Stephen Aselage, Senior Vice President of Global Commercial Operations for BioMarin Pharmaceutical.

About Kuvan

Kuvan(TM) (sapropterin dihydrochloride) Tablets is indicated to reduce blood phenylalanine (Phe) levels in patients with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin- (BH4-) responsive phenylketonuria (PKU). Kuvan is to be used in conjunction with a Phe-restricted diet.

The active ingredient in Kuvan, sapropterin dihydrochloride, is the synthetic form of 6R-BH4 (tetrahydrobiopterin), a naturally occurring enzyme cofactor that works in conjunction with phenylalanine hydroxylase (PAH) to metabolize Phe. BioMarin and Merck Serono estimate that Kuvan could be a potential treatment option for approximately 30 percent to 50 percent of the estimated 50,000 identified PKU patients in the developed world.

Kuvan has received orphan drug designation from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMEA). Kuvan has received seven years of market exclusivity in the United States. In November 2007, Merck Serono submitted a Marketing Authorization Application (MAA) to the EMEA for sapropterin dihydrochloride as an oral treatment for patients suffering from HPA due to PKU or BH4 deficiency. If approved in the EU, it will receive 10 years of market exclusivity for this indication.

About PKU

PKU, a genetic disorder affecting approximately 50,000 diagnosed patients in the developed world, is caused by a deficiency of the enzyme phenylalanine hydroxylase. PAH is required for the metabolism of phenylalanine, an essential amino acid found in most protein-containing foods. If the active enzyme is not present in sufficient quantities, Phe accumulates to abnormally high levels in the blood and becomes toxic to the brain, resulting in a variety of complications including severe mental retardation and brain damage, mental illness, seizures, tremors, and limited cognitive ability. To learn more about PKU, please visit http://www.PKU.com.

About Fairview Specialty Pharmacy

Fairview Specialty Pharmacy provides personal medication management services to patients who take high-cost or self-injected drugs for chronic conditions. Fairview Specialty Pharmacy ensures that patients receive their medications safely and on time via services including medication management and monitoring, free shipping anywhere in the US, and monthly refill reminder phone calls. All calls are answered by "live" pharmacists, and Patient Financial Advocates(SM) are available to help patients with insurance and billing issues. To learn more, visit http://www.FairviewSpecialtyPharmacy.org.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(TM) (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. For additional information, please visit http://www.BMRN.com.


'/>"/>
SOURCE Fairview Specialty Pharmacy
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Specialty Blades, Inc. Completes Acquisition of Popper and Sons, Inc.
2. EpiCept Corporation to Present at The New York Society of Security Analysts 11th Annual Biotech & Specialty Pharma Conference
3. Heska to Present at New York Society of Security Analysts Biotech/Specialty Pharma Conference
4. Albemarle Raises Prices of Specialty Aluminas
5. Franklin & Seidelmann Adds 31 Subspecialty Radiologists to Support Growing Demand for Subspecialty Expertise
6. Specialty Underwriters Alliance to Present at 2007 FBR Capital Markets Investor Conference
7. Survey shows gender differences are factor when surgeons in training choose a subspecialty
8. Packard Childrens Hospital Opens New South Bay Specialty Clinic Bringing Specialty Care Close to Home
9. Consumer Specialty Products Association Responds to European Study Investigating Spray Products and Asthma
10. Mylan Announces Management of Specialty Business, Dey L.P.
11. Consumer Specialty Products Association Highly Critical of NRDC Study on Home Air Fresheners
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... 25, 2016 , ... Experts from the American Institutes for ... Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR ... care planning, healthcare costs and patient and family engagement. , AIR researchers will ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. ... his M.D from the David Geffen School of Medicine at UCLA. He trained in ... to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced ... feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as a ... has released tools for healthy coping following a traumatic event. , Trauma sufferers tend ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Dr. Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile ... orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can ...
(Date:6/24/2016)... ... 24, 2016 , ... The Haute Beauty Network, affiliated with ... as a prominent plastic surgeon and the network’s newest partner. , Dr. ... handsome men, look naturally attractive. Plastic surgery should be invisible.” He stands by ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, ... Board will take whatever measures required to build a ... stock which is currently listed on the OTC Markets-pink ... Company Chairman and CEO, "We are seeing an anomaly ... to understand, not only by the Company, but shareholders ...
(Date:6/24/2016)... , June 24, 2016  Global Blood ... biopharmaceutical company developing novel therapeutics for the treatment ... today announced the closing of its previously announced ... stock, at the public offering price of $18.75 ... offering were offered by GBT. GBT estimates net ...
(Date:6/24/2016)... June 24, 2016 The Academy of Managed ... recommendations that would allow biopharmaceutical companies to more ... that make formulary and coverage decisions, a move that ... new medicines. The recommendations address restrictions in ... on the drug label, a prohibition that hinders decision ...
Breaking Medicine Technology: